CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

The Board of Directors (the "Board") of CG Oncology, Inc. (the "Company") has adopted the following Corporate Governance Guidelines (the "Guidelines") to assist the Board in the exercise of its responsibilities and to serve the interests of the Company and its stockholders. These Guidelines should be interpreted in the context of all applicable laws and the Company's certificate of incorporation, bylaws and other corporate governance documents. These Guidelines acknowledge the leadership exercised by the Board's standing committees and their chairs and are intended to serve as a flexible framework within which the Board may conduct its business and not as a set of legally binding obligations. The Guidelines are subject to modification from time to time by the Board as the Board may deem appropriate and in the best interest of the Company and its stockholders or as required by applicable laws and regulations.

I. THE BOARD

A. Size of the Board

The Company's certificate of incorporation provides that the number of directors will be fixed from time to time by the Board. The Nominating and Corporate Governance Committee will periodically review the size of the Board, and may make recommendations to the Board regarding the size of the Board that is most effective in relation to future operations.

B. <u>Independence of the Board</u>

Except as otherwise permitted by the applicable Nasdaq Stock Market LLC ("Nasdaq") rules, the Board will be comprised of a majority of directors who qualify as independent directors (the "Independent Directors") as required under Nasdaq rules.

Page 1 of 11 Rev 02 (Feb 2024)

ONCOLOGY TO

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

C. <u>Separate Sessions of Independent Directors</u>

The Independent Directors will meet in executive session without non-Independent Directors or management present on a regularly scheduled basis, but no less than twice per year.

D. <u>Lead Independent Director</u>

If the Chairman of the Board is a member of management or does not otherwise qualify as independent, the Independent Directors may elect a lead director (the "Lead Independent Director"). The Lead Independent Director's responsibilities include, but are not limited to: chairing meetings of the Independent Directors in executive session; facilitating communications between other directors and the Chairman of the Board and Chief Executive Officer; reviewing and approving matters, such as agenda items, schedule sufficiency, and, where appropriate, information provided to other directors; consulting with the Chairman and Chief Executive Officer on matters relating to corporate governance and Board performance; and performing such other duties as the Board may determine from time to time. Unless otherwise determined by the Board, the Lead Independent Director shall serve for an initial three-year term or, if earlier than the expiration of such three-year term, until such director's successor has been duly elected and qualified or until such director's earlier death, resignation or removal. The Board may modify its leadership structure in the future as it deems appropriate.

E. <u>Director Qualification Standards and Additional Selection Criteria</u>

The Nominating and Corporate Governance Committee, in recommending director candidates, and the Board, in nominating director candidates, will evaluate candidates in accordance with the qualification standards set forth in Attachment A to these Corporate Governance Guidelines. In addition, the

Page 2 of 11 Rev 02 (Feb 2024)

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

Nominating and Corporate Governance Committee and the Board may also consider the additional selection criteria listed in Attachment A.

F. <u>Director Orientation and Continuing Education</u>

Management will provide an orientation process for new directors, including background material on the Company and its business. As appropriate, management will provide opportunities for additional educational sessions for directors on matters relevant to the Company and its business.

G. <u>No Specific Limitation on Other Board Service</u>

The Board does not believe that its members should be prohibited from serving on boards of other organizations and has not adopted any guidelines limiting such activities. However, the Nominating and Corporate Governance Committee may take into account the nature of and time involved in a director's service on other boards and/or committees in evaluating the suitability of individual director candidates and current directors. Prior to accepting any position on the board of directors of any organization that is a potential competitor of the Company or which may raise conflict of interest concerns, whether for-profit or not-for-profit, current directors should notify the Chairperson of the Board or the Chairperson of the Nominating and Corporate Governance Committee.

Service on other boards and/or committees should be consistent with the Company's conflict of interest policies set forth below.

H. <u>Directors Who Resign or Materially Change Their Current Positions With</u> <u>Their Own Company or Become Aware of Circumstances that May Adversely</u> <u>Reflect upon the Director or the Company</u>

When a director, including any director who is currently an officer or employee of the Company, resigns or materially changes his or her position

Page 3 of 11 Rev 02 (Feb 2024)

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

with his or her employer or becomes aware of circumstances that may adversely reflect upon the director or the Company, such director should notify the Nominating and Corporate Governance Committee of such circumstances. The Nominating and Corporate Governance Committee will consider the circumstances, and may in certain cases recommend that the Board request that the director submit his or her resignation from the Board if, for example, continuing service on the Board by the individual is not consistent with the criteria deemed necessary for continuing service on the Board.

I. Term Limits

As each director is periodically subject to election by stockholders, the Board does not believe it is in the best interests of the Company to establish term limits at this time. Additionally, such term limits may cause the Company to lose the contribution of directors who have been able to develop, over a period of time, increasing insight into the Company's business and therefore can provide an increasingly significant contribution to the Board.

J. <u>Director Responsibilities</u>

The business and affairs of the Company will be managed by or under the direction of the Board, including through one or more of its committees as set forth in the bylaws and committee charters. Each director is expected to spend the time and effort necessary to properly discharge his or her responsibilities. These include:

- exercising their business judgment in good faith;
- acting in what they reasonably believe to be the best interest of all stockholders;
- becoming and remaining well-informed about the Company's business and operations and general business and economic trends affecting the Company; and

Page 4 of 11 Rev 02 (Feb 2024)

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

 ensuring that the business of the Company is conducted so as to further the long-term interests of its stockholders.

K. <u>Compensation</u>

The Board believes that director compensation should fairly pay directors for work required in a business of the Company's size and scope, and that compensation should align directors' interests with the long-term interests of stockholders. The Compensation Committee will review and make recommendations to the Board regarding the cash and equity compensation of directors. The Company's executive officers do not receive additional compensation for their service as directors.

Except as otherwise permitted by the applicable Nasdaq rules, members of the Audit Committee and Compensation Committee may not directly or indirectly receive any compensation from the Company other than their directors' compensation, including any compensation for service on committees of the Board and the receipt of equity incentive awards.

L. Conflicts of Interest

Directors are expected to avoid any action, position or interest that conflicts with the interests of the Company or gives the appearance of a conflict. If an actual or potential conflict of interest develops, the director should immediately report all facts regarding the matter to the Board. Any significant conflict must be resolved or the director should resign. If a director has a personal interest in a matter before the Board, the director must disclose the interest to the Board, excuse himself or herself from discussion on the matter and not vote on the matter. The Board may delegate any decision with respect to such transaction to the Audit Committee and/or Nominating and Corporate Governance Committee.

M. <u>Interaction with Institutional Investors</u>

Page 5 of 11 Rev 02 (Feb 2024)

© ONCOLOGY™

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

The Board believes that management speaks for the Company. Each director should refer all inquiries from institutional investors, the press or other third parties regarding the Company's operations or management. Individual Board members may, from time to time at the request of the management, meet or otherwise communicate with various constituencies that are involved with the Company. If comments from the Board are appropriate, they should, in most circumstances, come from the Chairperson of the Board.

N. Stock Ownership

The Company encourages directors to own shares of the Company's stock. However, the number of shares of the Company's stock owned by any director is a personal decision and, at this time, the Board has chosen not to adopt a policy requiring ownership by directors of a minimum number of shares.

O. Board Access to Senior Management

The Board will have complete access to Company management in order to ensure that directors can ask any questions and receive all information necessary to perform their duties. Directors should exercise judgment to ensure that their contact with management does not distract managers from their jobs or disturb the business operations of the Company. Any meetings or contacts that a director wishes to initiate may be arranged through the Chief Executive Officer or the Chairperson of the Board, or if neither is available or neither is appropriate, directly by the director. To the extent appropriate, such contact, if in writing, should be copied to the Chief Executive Officer of the Company.

P. Board Access to Independent Advisors

The Board committees may hire independent advisors as set forth in their applicable charters. The Board as a whole shall have access to any

Page 6 of 11 Rev 02 (Feb 2024)

ONCOLOGY TO

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

independent advisor retained by the Company, and the Board may hire any independent advisor it considers necessary to discharge its responsibilities.

Q. <u>Self-Evaluation</u>

The Nominating and Corporate Governance Committee will oversee a periodic assessment of the Board's and its committees' performance.

II. BOARD MEETINGS

A. <u>Frequency of Meetings</u>

The Board will meet at such times as the Board will from time to time determine. In addition, special meetings may be called from time to time as determined by the needs of the business. It is the responsibility of the directors to attend meetings.

B. Director Attendance

A director is expected to spend the time and effort necessary to properly discharge his or her responsibilities. Accordingly, a director is expected to regularly prepare for and attend meetings of the Board and all committees on which the director sits (including separate meetings of the Independent Directors), with the understanding that, on occasion, a director may be unable to attend a meeting. A director who is unable to attend a meeting of the Board or a committee of the Board is expected to notify the Chairperson of the Board or the Chairperson of the appropriate committee in advance of such meeting, and, whenever possible, participate in such meeting via teleconference in the case of an in-person meeting.

C. Attendance of Non-Directors

The Board encourages the Chairperson of the Board or of any committee to invite Company management and outside advisors or consultants from time

Page 7 of 11 Rev 02 (Feb 2024)

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

to time to participate in Board and/or committee meetings to (i) provide insight into items being discussed by the Board which involve the manager, advisor or consultant, (ii) make presentations to the Board on matters which involve the manager, advisor or consultant, and (iii) bring managers with high potential into contact with the Board. Attendance of non-directors at Board meetings is at the discretion of the Board.

D. Advance Receipt of Meeting Materials

Information regarding the topics to be considered at a meeting is essential to the Board's understanding of the business and the preparation of the directors for a productive meeting. To the extent feasible, the meeting agenda and any written materials relating to each Board meeting will be distributed to the directors sufficiently in advance of each meeting to allow for meaningful review of such agenda and materials by the directors. Directors are expected to have reviewed and be prepared to discuss all materials distributed in advance of any meeting.

III. COMMITTEE MATTERS

The Board currently has three (3) committees: (i) the Audit Committee, (ii) the Compensation Committee and (iii) the Nominating and Corporate Governance Committee. From time to time and depending upon the circumstances, the Board may form a new committee or disband a current committee. Each committee will perform its duties as assigned by the Board in compliance with the Company's bylaws and the committee's charter. It is the responsibility of the directors to attend the meetings of the committees on which they serve.

IV. SUCCESSION PLANNING

The Board (or a committee delegated by the Board) will (i) work on a periodic basis with the Chief Executive Officer to evaluate the Company's succession plans upon the Chief Executive Officer's retirement and in the event of an unexpected

Page 8 of 11 Rev 02 (Feb 2024)

© ONCOLOGY™

CG ONCOLOGY, INC.

CORPORATE GOVERNANCE GUIDELINES

occurrence, and (ii) periodically review the performance of the Chief Executive Officer.

V. OVERSIGHT OF RISK MANAGEMENT

The Board and the Board committees shall have an active role in overseeing management of the Company's risks. The Board shall regularly review information regarding the Company's credit, liquidity and operations, as well as the risks associated with each. The Company's Compensation Committee shall be responsible for overseeing the management of risks relating to the Company's executive compensation plans and arrangements. The Company's Audit Committee shall oversee management of financial risks, including with respect to cybersecurity. The Nominating and Corporate Governance Committee shall manage risks associated with the independence of the Board and potential conflicts of interest. While each committee shall be responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed through committee reports about such risks.

VI. ETHICS HOTLINE

The Audit Committee will cause the Company to implement, maintain and monitor an ethics hotline that is designed to receive anonymous reports of any known or suspected violations of the Company's Code of Business Conduct and Ethics or any applicable laws and regulations. The Audit Committee will investigate any reports received through the ethics hotline and report to the Board periodically with respect to the information received through the ethics hotline and any related investigations.

* * * * *

Page 9 of 11 Rev 02 (Feb 2024)

CG ONCOLOGY, INC.



CORPORATE GOVERNANCE GUIDELINES Attachment A

Director Qualification Standards and Additional Selection Criteria

Director Qualification Standards:

The Nominating and Corporate Governance Committee, in recommending director candidates for election to the Board, and the Board, in nominating director candidates, will consider candidates who have a high level of personal and professional integrity, strong ethics and values and the ability to make mature business judgments.

Additional Selection Criteria:

In evaluating director candidates, the Nominating and Corporate Governance Committee and the Board may also consider the following criteria as well as any other factor that they deem to be relevant:

- A. The candidate's experience in corporate management, such as serving as an officer or former officer of a publicly held company;
- B. The candidate's experience as a board member of another publicly held company;
- C. The candidate's professional and academic experience relevant to the Company's industry;
- D. The strength of the candidate's leadership skills;
- E. The candidate's diversity of background and perspective, including, but not limited to, with respect to age, gender, sexual orientation, race, ethnicity, place of residence and specialized experience;
- F. The candidate's experience in finance and accounting and / or executive compensation practices; and
- G. Whether the candidate has the time required for preparation, participation and attendance at Board meetings and committee meetings, if applicable.

In addition, the Board will consider whether there are potential conflicts of interest with the candidate's other personal and professional pursuits.

Page 10 of 11 Rev 02 (Feb 2024)

CG ONCOLOGY, INC.



CORPORATE GOVERNANCE GUIDELINES Attachment A

The Board should monitor the mix of specific experience, qualifications, skills and backgrounds of its directors in order to assure that the Board, as a whole, has the necessary tools to perform its oversight function effectively in light of the Company's business and structure and that its composition meets any applicable Nasdaq diversity requirements.

Page 11 of 11 Rev 02 (Feb 2024)